Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
02 Diciembre 2024 - 6:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Scott Harris, Chief Medical
Officer at Altimmune, will present body composition data from the
Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity
and participate in a panel discussion at the Cachexia Regulatory
& Trials Update Workshop of the 17th International Conference
of the Society on Sarcopenia, Cachexia & Wasting Disorders in
Washington, D.C.
Details for the panel discussion are as
follows:
|
Title: |
Muscle Wasting in Weight Loss Therapy |
|
Session: |
Treatment Approaches to Address Muscle Wasting in the Context of
Obesity Therapy & Regulatory Issues |
|
Presenter: |
Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
|
Date/Time: |
Friday, December 6, 2024 at 9:30 am ET |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please visit
www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Greg WeaverChief Financial
OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified
individual.
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Altimmune (NASDAQ:ALT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
